MYCN and neuroblastoma: UNC0642, a more potent analog of UNC0638 with better in vivo pharmacokinetics, inhibited growth in several pediatric cancers, including MYCN-amplified neuroblastoma [140], Ewing sarcoma [141], and ARMS [142,143].